p>"We continue to be encouraged by the long-term follow-up data from this
trial, particularly in the treatment-naive and complete remission
populations," said Richard Ghalie, M.D., Favrille's Chief Medical Officer.
"These data reaffirm our confidence in our pivotal Phase 3 trial of
Specifid following Rituxan, which has a high proportion of each of the
populations who appear to benefit the most. We look forward to the primary
endpoint data in our Phase 3 trial next summer and ultimately to advancing
this important therapy to the marketplace so that it may be made broadly
available to patients in need."
Additional Specifid-related posters at the ASH Annual Meeting will
include:
-- A presentation by Dr. John Timmerman from the University of California,
Los Angeles on Sunday will present data comparing Id-KLH active
immunotherapy generated in insect cells (Specifid) to Id-KLH produced
in a traditional mammalian cell manufacturing process. The analysis
concludes that Id-KLH produced via insect cells results in a more
immunogenic response in a number of in vitro and in vivo assays, and
may lead to improved activity of the final Id-KLH active immunotherapy
product.
-- A presentation by Dr. David Maloney of the Fred Hutchinson Cancer
Research Center on Monday analyzing the role of Fc receptor
polymorphisms on the outcome of treatment with Rituxan followed by
Specifid. The data suggest that long-term progression-free survival
following a treatment regimen of Rituxan plus Specifid does not
correlate with inheritance of particular Fc receptor polymorphisms nor
with the production of anti-idiotypic antibody and therefore may rely
more on a cell-mediated immune response.
A copy of each poster presentation will be available on Favrille's
website at http://www.favrille.com
'/>"/>
SOURCE Favrille, Inc. Copyright©2007 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 Related medicine news :1.
Virginia Tech Report Has National Importance2.
New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites3.
GAO Report Confirms: Medicare Underpays for Anesthesia Services; Nurse Anesthetists Assure Seniors Access to Safe Anesthesia Care4.
Haemacure Reports Third Quarter 2007 Results5.
Report on patients access to cancer drugs uses flawed methods to reached flawed conclusions6.
Biotech Finishes on a High in August, Burrill Report Says7.
First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion8.
Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best9.
MDS Reports Third Quarter 2007 Results10.
First New York/New Jersey Health Care Report Card Released11.
Authentidate Holding Corp. to Report Fourth Quarter and Fiscal 2007 Year End Results on Thursday, September 13, 2007